MarginsXMarginsX
Home › Markets › Health Care › KTTA

Pasithea Therapeutics Corp. (KTTA)

KTTA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5000
-4.21% on the day
Market cap
$16.7M
Nano cap
Revenue · 2022
$487K
+3130.4% on 2021
Net income · 2022
-$13.9M
-2864.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1841330/000121390023024755/0001213900-23-024755-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerKTTA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001841330

Financials · 2022

LineValue
Revenue$487K
Net income-$13.9M
Operating income-$12.6M
Net margin-2864.3%
Operating margin-2587.3%
Revenue growth+3130.4%
Cash$33.1M
Total assets$45.2M
P/E (computed)Net income was not positive
P/S (computed)34.3×

Warning signs

Cash runway
30.8 months
$45.7M cash at June 30, 2026
Share count, 1 year
+393.7%
2025-11-12 to 2026-11-12 · +3427.7% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$178K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Management considered whether or not there are conditions or events, in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern, and concluded that there are none as it estimates that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of t"
10-Q 2026-11-13
Cash and burn$45.7M cash; operating cash flow -$4.4M a quarter.Report 2026-06-30
Shares outstanding36,752,548 (2026-11-12); 7,443,577 a year earlier; 20,836,623 three years earlier. 3y figure adjusted for split (1-for-20 overall).Cover page 2026-11-12
Reverse splits, 3 years1; latest 1-for-20 on 2024-01-02Source 2024-01-02
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-21
Delisting25-NSE filed25-NSE 2026-09-16
AuditorCBIZ CPAs P.C., Hartford, Connecticut, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $178K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$5.3M-$4.7M$45.7MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$2.9M-$4.8M$50.4MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$10.1M-$5.4M$55.2MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$3.0M-$2.9M$4.1MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$3.7M-$3.9M$7.2MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$3.6M-$3.1M$5.3MNo debt tagsNeeds four quarters10-Q 2025-08-14
Q4 2024
2024-12-31
Not filed-$3.2M-$2.4M$6.9MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$3.0M-$3.1M$9.4MNo debt tagsNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-9.8%
1 month+23.1%
3 months+9.2%
Year to date-59.5%
1 year-25.7%
From 52-week high-64.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
QNRXQuoin Pharmaceuticals Ltd.$3.56-3.78%$17.1M
NCELNewcelX Ltd.$2.75+5.36%$15.9M
CNTXContext Therapeutics Inc.$0.1659-8.24%$15.2M
LPCNLipocine Inc.$1.66-2.92%$18.4M
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier